Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide

An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03509545

Enrollment

Registered

2018-04-26

Start date

2021-06-30

Completion date

2022-06-30

Last updated

2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Body Weight Changes

Keywords

natriuresis

Brief summary

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice daily Furosemide on 24-hour sodium excretion.

Detailed description

To compare the effects of 40 mg once-daily Torsemide ER to 40 mg twice-daily Furosemide on changes in body weight after two weeks of treatment. To compare the frequency and volume of urine passed in 24 hours. To compare the patients' quality of life and levels of natriuretic peptide between the two sets of patients.

Interventions

DRUGCHF Patients: ER Torsemide 40 mg

ER Torsemide 40mg given once daily to CHF patients

DRUGCHF Patients: Furosemide 40 mg

Stable CHF patients taking twice-daily 40 mg Furosemide

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients of either gender over 18 years of age with clinical diagnosis of CHF and on a stable dose of 40 mg Furosemide.

Exclusion criteria

* Requirement for any other diuretic, history of cardiac dysrhythmia, other concurrent cardiovascular illness.

Design outcomes

Primary

Measure	Time frame	Description
change in 24-hour sodium excretion compared to baseline	24 hours	the difference in 24 hour sodium excretion between ER Torsemide and Furosemide

Secondary

Measure	Time frame	Description
Changes in body weight	2 weeks	Body weight changes will be compared between the two arms

Countries

India

Contacts

PRINCIPAL_INVESTIGATORAnil K, MD

Syngene

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026